Page 69 - 《中国药房》2022年9期
P. 69
升高,从而促进细胞凋亡。同时,由于 Bcl-2 与 Beclin1 杂志,2019,39(8):608-612.
的结合抑制了 Beclin1 参与细胞自噬激活,所以 GLA 10 [ 8 ] NANA X,MENGMENG L,JIAXIN W,et al. Ivermectin
μg/mL 的作用主要表现为促进细胞凋亡。相较而言, induces apoptosis of esophageal squamous cell carcinoma
GLA 5 μg/mL 作用于 HCCLM3 细胞 24 h 后,细胞中 via mitochondrial pathway[J]. BMC Cancer,2021,21(1):
Bcl-2 与 Beclin1 的结合较少,因此,该剂量 GLA 促进细 1307.
[ 9 ] ZHU J W,SUN Y,LU Y,et al. Glaucocalyxin A exerts
胞自噬的作用较为明显,透射电镜下可见细胞内出现较
anticancer effect on osteosarcoma by inhibiting GLI1
多自噬小体。以往研究也显示,Bcl-2 与细胞凋亡蛋白
nuclear translocation via regulating PI3K/Akt pathway[J].
和细胞自噬蛋白存在交叉反应 [18-19] ,提示Bcl-2极有可能
Cell Death Dis,2018,9(6):708.
在细胞自噬与凋亡之间起关键性调控作用。
[10] LAMERS F,SCHILD L,DEN HARTOG I J,et al. Targeted
研究显示,多种中草药活性成分均能够诱发肿瘤细
Bcl2 inhibition effectively inhibits neuroblastoma tumour
胞凋亡并激活细胞自噬,对肿瘤细胞的生物学行为进行 growth[J]. Eur J Cancer,2012,48(16):3093-3103.
双向调节 。笔者团队前期研究结果显示,GLA对人肝 [11] TOUZEAU C,MACIAG P,AMIOT M,et al. Targeting
[20]
癌 HCCLM3 细胞的炎症反应、侵袭能力、迁移能力具有 Bcl-2 for the treatment of multiple myeloma[J]. Leukemia,
双向调节作用,且效果呈剂量效应关系 。本研究结果 2018,32(9):1899-1907.
[7]
显示,GLA 可通过线粒体途径促进细胞自噬与凋亡,并 [12] HAN L N,ZHANG Q,DAIL M,et al. Concomitant targe-
对 Bcl-2 与 Beclin1 的结合与解离具有双向调节作用,提 ting of Bcl2 with venetoclax and MAPK signaling with
示 GLA 可能通过 Bcl-2/Beclin1 靶点调节 HCCLM3 细胞 cobimetinib in acute myeloid leukemia models[J]. Haema-
自噬与凋亡,作用效果依然可能呈剂量效应关系。 tologica,2020,105(3):697-707.
综上所述,GLA 可能通过 Bcl-2/Beclin1 靶点调节 [13] KAPOOR I,BODO J,HILL B T,et al. Targeting Bcl-2 in
B cell malignancies and overcoming therapeutic resis-
HCCLM3 细胞自噬与凋亡,且作用效果与剂量密切
tance[J]. Cell Death Dis,2020,11(11):941.
相关。
[14] SHI C S,KEHRL J H. Bcl-2 regulates pyroptosis and
参考文献
necroptosis by targeting BH3-like domains in GSDMD
[ 1 ] REN L L,WANG J J,CHEN G G. Preparation,optimiza-
and MLKL[J]. Cell Death Discov,2019,5:151.
tion of the inclusion complex of glaucocalyxin A with sul-
[15] YANG M,YANG X M,YIN D H,et al. Beclin1 enhances
fobutylether-β-cyclodextrin and antitumor study[J]. Drug
cisplatin-induced apoptosis via Bcl-2-modulated autophagy
Deliv,2019,26(1):309-317.
in laryngeal carcinoma cells Hep-2[J]. Neoplasma,2018,
[ 2 ] TANG L S,JIN X F,HU X H,et al. Glaucocalyxin A in-
65(1):42-48.
hibits the growth of liver cancer Focus and SMMC-7721
[16] ZHANG L D,FENG Q L,WANG Z T,et al. Progesterone
cells[J]. Oncol Lett,2016,11(2):1173-1178.
receptor antagonist provides palliative effects for uterine
[ 3 ] HAN M H,LI Z T,GUO Y F,et al. A nanoparticulate
leiomyoma through a Bcl-2/Beclin1-dependent mechanism
drug-delivery system for glaucocalyxin A:formulation,
[J]. Biosci Rep,2019,39(7):BSR20190094.
characterization,increased in vitro,and vivo antitumor
[17] ZHANG D G,ZHAO T,HOGSTRAND C,et al. Oxidized
activity[J]. Drug Deliv,2016,23(7):2457-2463.
fish oils increased lipid deposition via oxidative stress-
[ 4 ] LIN W F,XIE J L,XU N J,et al. Glaucocalyxin A induces
mediated mitochondrial dysfunction and the CREB1-
G2/M cell cycle arrest and apoptosis through the PI3K/Akt
Bcl2-Beclin1 pathway in the liver tissues and hepatocytes
pathway in human bladder cancer cells[J]. Int J Biol Sci,
of yellow catfish[J]. Food Chem,2021,360:129814.
2018,14(4):418-426.
[18] LINDQVIST L M,VAUX D L. Bcl2 and related prosur-
[ 5 ] SHI F Z,XUE D F,JIANG Q K,et al. Glaucocalyxin A in-
vival proteins require BAK1 and BAX to affect autophagy
duces apoptosis and autophagy in tongue squamous cell
[J]. Autophagy,2014,10(8):1474-1475.
carcinoma cells by regulating ROS[J]. Cancer Chemother
[19] LIU J,LIU W J,YANG H. Balancing apoptosis and auto-
Pharmacol,2021,88(2):235-246.
phagy for Parkinson’s disease therapy:targeting BCL-2
[ 6 ] FERNÁNDEZ Á F,SEBTI S,WEI Y J,et al. Disruption
[J]. ACS Chem Neurosci,2019,10(2):792-802.
of the Beclin1-Bcl2 autophagy regulatory complex pro-
[20] 邵鑫,蒋先虹,王瑞,等.紫草素对人结肠癌细胞HCT116
motes longevity in mice[J]. Nature,2018,558(7708):
自噬和凋亡的影响[J].中国药房,2021,32(1):51-55.
136-140.
(收稿日期:2021-10-26 修回日期:2022-03-06)
[ 7 ] 朱琳琳,徐祉轩,张明明.蓝萼甲素通过IL-6调节HCCLM3
(编辑:舒安琴)
细胞STAT3信号通路的表达[J].中华微生物学和免疫学
中国药房 2022年第33卷第9期 China Pharmacy 2022 Vol. 33 No. 9 ·1087 ·